|
Combined Use of Study Drug and a marketed SERM (Selective Estrogen Receptor Modulator) in Postmenopausal Women with Osteoporosis Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Combined Use of Study Drug and a marketed SERM (Selective Estrogen Receptor Modulator) in Postmenopausal Women with Osteoporosis conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Combined Use of Study Drug and a marketed SERM (Selective Estrogen Receptor Modulator) in Postmenopausal Women with Osteoporosis Clinical research trials and Combined Use of Study Drug and a marketed SERM (Selective Estrogen Receptor Modulator) in Postmenopausal Women with Osteoporosis health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Combined Use of Study Drug and a marketed SERM (Selective Estrogen Receptor Modulator) in Postmenopausal Women with Osteoporosis. Combined Use of Study Drug and a marketed SERM (Selective Estrogen Receptor Modulator) in Postmenopausal Women with Osteoporosis Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Combined Use of Study Drug and a marketed SERM (Selective Estrogen Receptor Modulator) in Postmenopausal Women with Osteoporosis clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Combined Use of Study Drug and a marketed SERM (Selective Estrogen Receptor Modulator) in Postmenopausal Women with Osteoporosis condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combined Use of Study Drug and a marketed SERM (Selective Estrogen Receptor Modulator) in Postmenopausal Women with Osteoporosis  Combined Use of Study Drug and a marketed SERM (Selective Estrogen Receptor Modulator) in Postmenopausal Women with Osteoporosis
Combined Use of Study Drug and a marketed SERM (Selective Estrogen Receptor Modulator) in Postmenopausal Women with Osteoporosis
For Condition: Osteoporosis, Postmenopausal
Status: No longer recruiting
Sponsor(s): Eli Lilly and Company ,
Synopsis: The purpose of this study is to compare treatment with both Study Drug and a SERM to treatment with Study Drug alone. The study will evaluate any side effects that may be associated with the two drugs and may help to determine whether Study Drug and a SERM together can help patients with osteoporosis more than Study Drug alone.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 45 Years/85 Years
Genders: Female
Protocol Entry Criteria: Inclusion Criteria - Must be diagnosed with osteoporosis. - Must be female, age 45 through 85. - Must be at least 5 years postmenopausal. - Must be free of other severe or chronically disabling conditions. - Must be able to properly use injection device. Exclusion Criteria - Must not have bone diseases other than osteoporosis. - Must not have history of certain cancers. - Must not have certain medical diseases (inflammatory bowel disease, malabsorption syndrome, kidney or bladder stones, venous thrombi or emboli, recent vaginal bleeding due to unknown causes). - Must not have taken or are currently taking certain types of medicines. - Must not have known allergy to the study agent or SERM.
Total Enrollment:
Location and Contact Information:
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Anaheim, California, 92801
United States
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Oakland, California, 94612
United States
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Baltimore, Maryland, 21204
United States
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Portland, Oregon, 97213
United States
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Duncansville, Pennsylvania, 16635
United States
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Dallas, Texas, 75231
United States
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Altamonte Springs, Florida, 32714
United States
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Voorhees, New Jersey, 08043
United States
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Chicago, Illinois, 60622
United States
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Cleveland, Ohio, 44195
United States
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Cedar Rapids, Iowa, 52401
United States
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Hagerstown, Maryland, 21740
United States
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician".
Oklahoma City, Oklahoma, 73109
United States
Additional Information:
Study ID Numbers: 6817;
Study Start Date:
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00046137
Other Osteoporosis, Postmenopausal Studies:
1. Combined Use of Study Drug and a marketed SERM (Selective Estrogen Receptor Modulator) in Postmenopausal Women with Osteoporosis
2. Patient- and Physician-Based Osteoporosis Education
Related Studies:
Other Osteoporosis, Postmenopausal Clinical Trials
Other California Clinical Trials
Other Oakland Clinical Trials
Combined Use of Study Drug and a marketed SERM (Selective Estrogen Receptor Modulator) in Postmenopausal Women with Osteoporosis
|
|
|
|
|
|
|
|
